Metraipolis › archive › dc_56ea7bbc5a35
Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case report — Europe PMC PMID:41846922
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41846922
- DOI
- 10.3389/fimmu.2026.1721711
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T10:04:56.494Z
- SHA-256 of the archived text
003e2ebdbe71e5a054989aad1c9635cbb52ba33ff740442b1a03add58ff99cb2- Stable URL of this page
https://metraipolis.com/documento/dc_56ea7bbc5a35
How to cite
Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case report — Europe PMC PMID:41846922 — Europe PMC (en), https://europepmc.org/article/MED/41846922 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_56ea7bbc5a35 (Metraipolis archive dc_56ea7bbc5a35, sha256 003e2ebdbe71e5a054989aad1c9635cbb52ba33ff740442b1a03add58ff99cb2)
BibTeX
@misc{dc56ea7bbc5a35,
title = {Fulminant multi-organ myositis as a rare immune-related adverse event of nivolumab-relatlimab (Opdualag) therapy in metastatic melanoma: a case report — Europe PMC PMID:41846922},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41846922},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_56ea7bbc5a35; sha256 003e2ebdbe71e5a054989aad1c9635cbb52ba33ff740442b1a03add58ff99cb2},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41846922. Agents can read the archived copy with the MCP tool read_document.